Phase III
The month of July is a slow one for the U.S. Food and Drug Administration (FDA), at least in terms of scheduled approval dates. Here’s a look at the three PDUFA dates the agency has on its calendar for the month.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
The U.S. Food and Drug Administration (FDA) gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adults that express a specific biomarker.
Following an operational review, ImmunoGen will prioritize continued development of mirvetuximab, as well as a select portfolio of three earlier-stage product candidates.
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.
Biotech and pharma companies from across the globe share pipeline and business updates.
The higher doses of type 2 diabetes drug Trulicity significantly reduced A1C and also showed superiority in weight reduction. Here’s everything you should know about the drug.
Aldeyra Therapeutics reported that its reproxalap failed to meet its primary or secondary endpoints in noninfectious anterior uveitis.
Data shows the long-term efficacy and tolerability as well as the continued ability of Onpattro to reverse or halt neuropathy progression.
The partial clinical hold was lifted after the company revised the study protocol for the trial. The partial clinical hold remains on other multiple myeloma trials involving venetoclax.
PRESS RELEASES